Zydus Cadila acquires US-based Sentynl Therapeutics

The transaction will be earnings per share accretive

Zydus Cadila on Thursday has said that it has acquired Sentynl Therapeutics, a US-based pharma company specialised in marketing of products in the pain management segment.

The transaction will be EPS (earnings per share) accretive, Zydus Cadila said in a statement.

With this acquisition, it said the company makes a foray into the specialty pain market in the US valued at USD 8 billion.

"It gains access to the specialty distribution network and a large prescriber base....This acquisition will also enable the Zydus group to leverage its existing assets in the US," it added.

Speaking on the development Pankaj R Patel, Chairman and Managing Director, Zydus Cadila said: "...The acquisition of Sentynl opens up a new business avenue for us in the specialty prescription segment in the US."

It said the acquisition is solely funded by Bank of Tokyo-Mitsubishi UFJ.

Leerink Partners LLC acted as exclusive financial advisor to Sentynl on the transaction.